Amedeo Smart

Free Medical Literature Service

 

Amedeo

Stem Cell Research
  Free Subscription

Articles published in
Bone Marrow Transplant
    April 2025
  1. IBRAHIMOVA A, Khoury R, Jodele S, Grimley M, et al
    Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Apr 29. doi: 10.1038/s41409-025-02601.
    >> Share

  2. PERMINOVA M, Shelikhova L, Klimentova M, Skvortsova Y, et al
    Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial.
    Bone Marrow Transplant. 2025 Apr 25. doi: 10.1038/s41409-025-02566.
    >> Share

  3. TARANTINO S, Labopin M, Zeiser R, Stelljes M, et al
    Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02596.
    >> Share

  4. OZTURK G, Yesilipek MA, Akcay A, Uygun V, et al
    Effect of genetic mutations on outcomes of stem cell transplantation in children with hemophagocytic lymphohistiocytosis.
    Bone Marrow Transplant. 2025 Apr 22. doi: 10.1038/s41409-025-02592.
    >> Share

  5. CHUMNUMSIRIWATH P, Vittayawacharin P, Ramos-Perez J, Jeyakumar D, et al
    Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT).
    Bone Marrow Transplant. 2025 Apr 22. doi: 10.1038/s41409-025-02595.
    >> Share

  6. NAIR V, Kathrotiya M, Shirure V, Bhise S, et al
    Feasibility and efficacy of partial replacement of post transplantation cyclophosphamide with bendamustine on day +4 for graft versus host disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2025 Apr 21. doi: 10.1038/s41409-025-02581.
    >> Share

  7. RAVAIOLI F, Colecchia A, Peccatori J, Pagliara D, et al
    Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT), the ELASTOVOD STUDY: an investigator-initiated, prospective, multicent
    Bone Marrow Transplant. 2025 Apr 19. doi: 10.1038/s41409-025-02570.
    >> Share

  8. BERGLAND BS, Remberger M, Tjonnfjord GE, Vo CD, et al
    Should a young matched unrelated donor be preferred over an older matched related donor in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome?
    Bone Marrow Transplant. 2025 Apr 18. doi: 10.1038/s41409-025-02579.
    >> Share

  9. BAYOUMY M, Raffa EH, Alharbi AA, Abosoudah I, et al
    Outcomes of Hematopoietic Stem Cell Transplantation in children with Sickle Cell Disease: Does donor Sickle cell trait status matter?
    Bone Marrow Transplant. 2025 Apr 18. doi: 10.1038/s41409-025-02572.
    >> Share

  10. GALEANO S, Bonfim C, Karduss A, Jaimovich G, et al
    Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors.
    Bone Marrow Transplant. 2025 Apr 18. doi: 10.1038/s41409-025-02600.
    >> Share

  11. LETAILLEUR V, Jullien M, Garnier A, Peterlin P, et al
    Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Apr 16. doi: 10.1038/s41409-025-02589.
    >> Share

  12. LYSANDROU M, Kefala D, Vinnakota JM, Savvopoulos N, et al
    Regulatory T cell therapy for Graft-versus-Host Disease.
    Bone Marrow Transplant. 2025 Apr 16. doi: 10.1038/s41409-025-02553.
    >> Share

  13. VERBEEK AB, von Asmuth EGJ, van den Akker EB, Jansen-Hoogendijk AM, et al
    Pre-transplant inflammation and its associations with acute GvHD and mortality in pediatric allogeneic hematopoietic stem cell transplantation patients.
    Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02583.
    >> Share

  14. BREHM N, Biavasco F, Clausen J, Jung J, et al
    Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey.
    Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02586.
    >> Share

  15. BERGENS MA, Lowder YP, Li Y, Johnson EJ, et al
    Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.
    Bone Marrow Transplant. 2025 Apr 12. doi: 10.1038/s41409-025-02587.
    >> Share

  16. GONZALEZ VICENT M, Pereto A, Zubicaray J, Molina B, et al
    Outcomes in allogeneic hematopoietic stem cell transplantation for Fanconi anemia.
    Bone Marrow Transplant. 2025 Apr 12. doi: 10.1038/s41409-025-02591.
    >> Share

  17. SENAPATI J, Garcia-Manero G, DiNardo CD, Deshmukh I, et al
    Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Apr 11. doi: 10.1038/s41409-025-02590.
    >> Share

  18. ORTI G, Dachy G, Graham CE, Peric Z, et al
    Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practi
    Bone Marrow Transplant. 2025 Apr 9. doi: 10.1038/s41409-025-02567.
    >> Share

  19. SUREDA A, Pavlovsky A, Haidar D, Kristo F, et al
    Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557.
    >> Share

  20. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study by the ATL working group of the Japanese Society for
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02563.
    >> Share

  21. LOPEZ-CORRAL L, Blazquez-Goni C, Perez-Lopez E, Martin-Dominguez FM, et al
    GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02562.
    >> Share

  22. LIU J, Mai Y, Jing Z, Zhao L, et al
    Protective factors, management and prognosis of mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia in children.
    Bone Marrow Transplant. 2025 Apr 6. doi: 10.1038/s41409-025-02577.
    >> Share

  23. BARANWAL A, Kassis R, Hassan K, Kutzke J, et al
    Outcomes of attenuated dose fludarabine and melphalan based conditioning regimen in patients undergoing allogeneic stem cell transplant: a propensity score-matched analysis.
    Bone Marrow Transplant. 2025 Apr 5. doi: 10.1038/s41409-025-02565.
    >> Share

  24. PENA M, Martinez DF, Paviglianiti A, Balaguer A, et al
    Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC.
    Bone Marrow Transplant. 2025 Apr 2. doi: 10.1038/s41409-025-02559.
    >> Share

  25. CHEN W, Zhang Y, Guo J, Wu X, et al
    The pre-ASCT serum albumin and pre-ASCT dFLC are prognostic markers in renal light chain amyloidosis patients treated with autologous stem cell transplantation.
    Bone Marrow Transplant. 2025 Apr 1. doi: 10.1038/s41409-025-02575.
    >> Share

  26. MICHONNEAU D, Malard F, Le Grand S, Magro L, et al
    Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2025 Apr 1. doi: 10.1038/s41409-025-02554.
    >> Share

    March 2025
  27. MINAKATA D, Fujiwara SI, Honda S, Tominaga R, et al
    Impact of daratumumab on the development of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.
    Bone Marrow Transplant. 2025 Mar 23. doi: 10.1038/s41409-025-02558.
    >> Share

  28. SANTORO N, Schmid C, de Witte M, Roeven MWH, et al
    Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT.
    Bone Marrow Transplant. 2025 Mar 23. doi: 10.1038/s41409-025-02555.
    >> Share

  29. PINANA JL, Mico-Cerda M, Gomez D, Perez A, et al
    Early ribavirin reduce RSV symptoms duration in post-allogeneic stem cell transplant: challenges in symptoms duration assessment.
    Bone Marrow Transplant. 2025 Mar 22. doi: 10.1038/s41409-025-02549.
    >> Share

  30. STORCK TN, Morsink LM, Biswana A, Hazenberg CLE, et al
    Donor lymphocyte infusions after HLA-identical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in acute myeloid leukemia patients.
    Bone Marrow Transplant. 2025 Mar 19. doi: 10.1038/s41409-025-02552.
    >> Share

  31. KLEINSCHMIDT K, Penkivech G, Troeger A, Foell J, et al
    alphass T-cell depleted haploidentical stem cell transplantation for pediatric and young adult patients with transfusion-dependent thalassemia.
    Bone Marrow Transplant. 2025 Mar 18. doi: 10.1038/s41409-025-02546.
    >> Share

  32. GAVRIILAKI E, Evangelidis P, Kotsiou N, Sakellari I, et al
    Antifungal prescription and stewardship in hematology and hematopoietic stem cell transplantation units worldwide: an international survey of EHA-SWG Infections in Hematology.
    Bone Marrow Transplant. 2025 Mar 9. doi: 10.1038/s41409-025-02545.
    >> Share

  33. SCHULZ E, Pirsl F, McGraw K, Nousome D, et al
    Prevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease.
    Bone Marrow Transplant. 2025 Mar 8. doi: 10.1038/s41409-025-02537.
    >> Share

  34. CALVO C, Mornet C, Storey C, Halfon-Domenech C, et al
    Adult height and growth hormone therapy in childhood acute lymphoblastic leukemia survivors treated with total body irradiation and hematopoietic stem cell transplantation before puberty.
    Bone Marrow Transplant. 2025 Mar 3. doi: 10.1038/s41409-025-02532.
    >> Share

  35. ZHEN S, Liu L, Zhang X, Wang J, et al
    Increased Epstein-Barr virus reactivation but similar incidence of post-transplant lymphoproliferative disorders due to pre-emptive rituximab therapy following allogeneic hematopoietic stem cell transplantation in the letermovir era for cytomegaloviru
    Bone Marrow Transplant. 2025 Mar 3. doi: 10.1038/s41409-025-02542.
    >> Share

    February 2025
  36. KOLLER PB, Othman T, Yang D, Mokhtari S, et al
    Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect.
    Bone Marrow Transplant. 2025 Feb 27. doi: 10.1038/s41409-025-02523.
    >> Share

  37. VIDAL A, Bora C, Jarisch A, Pape J, et al
    Impact of haematopoietic stem cell transplantation for benign and malignant haematologic and non-haematologic disorders on fertility: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2025 Feb 26. doi: 10.1038/s41409-025-02520.
    >> Share

  38. MUCHTAR E, Dispenzieri A, Sanchorawala V, Hassan H, et al
    A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis.
    Bone Marrow Transplant. 2025 Feb 24. doi: 10.1038/s41409-025-02535.
    >> Share

  39. RANDI BA, Higashino HR, Ponzio V, Abdala E, et al
    COVID-19 prior to hematopoietic stem cell transplantation increases the risk of acute graft-versus-host disease but does not affect overall mortality.
    Bone Marrow Transplant. 2025 Feb 21. doi: 10.1038/s41409-025-02536.
    >> Share

  40. LIN MH, Huang XJ, Xu LP, Wang Y, et al
    The haematopoietic cell transplantation comorbidity index predicts clinical outcomes for severe aplastic anaemia patients after haploidentical haematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Feb 13. doi: 10.1038/s41409-025-02513.
    >> Share

  41. ZHOU J, Wang F, Yang S, Zhang Y, et al
    Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02528.
    >> Share

  42. SANZ J, Labopin M, Versluis J, Blaise D, et al
    Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02527.
    >> Share

  43. MODI B, Ngo D, Chen J, Yang D, et al
    Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience.
    Bone Marrow Transplant. 2025 Feb 4. doi: 10.1038/s41409-024-02498.
    >> Share

  44. TAN JY, Koh LP, Woon YK, Heng KK, et al
    A formula using day 4 parameters to predict next-day peripheral blood stem cell yield in healthy haematopoietic stem cell donors.
    Bone Marrow Transplant. 2025 Feb 3. doi: 10.1038/s41409-024-02503.
    >> Share

    January 2025
  45. RODRIGUES AM, Fernandes JF, Gregianin L, Nichele S, et al
    Hematopoietic stem cell transplantation in inborn errors of metabolism-a retrospective analysis on behalf of the pediatric disease working party from the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2025 Jan 26. doi: 10.1038/s41409-025-02512.
    >> Share

  46. SINDONI MM, Limido F, Toso A, Lucchini G, et al
    aGvHDtrackR and cGvHDtrackR: shiny applications for graft versus host disease management and clinical data collection.
    Bone Marrow Transplant. 2025 Jan 9. doi: 10.1038/s41409-025-02509.
    >> Share

  47. WANG Q, Liu M, Zhang S, Gao L, et al
    Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Jan 7. doi: 10.1038/s41409-024-02502.
    >> Share

  48. HUANG XB, Yang X, Li CL, Zhang R, et al
    Correction: Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.
    Bone Marrow Transplant. 2025 Jan 6. doi: 10.1038/s41409-024-02470.
    >> Share

    December 2024
  49. YU F, Niu J, Yang J, Hou J, et al
    Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.
    Bone Marrow Transplant. 2024 Dec 20. doi: 10.1038/s41409-024-02500.
    >> Share

  50. BRIJS J, Peczynski C, Boreland W, Cuoghi A, et al
    Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working Party.
    Bone Marrow Transplant. 2024 Dec 13. doi: 10.1038/s41409-024-02497.
    >> Share

  51. FALCO-ROGET A, Raiola AM, Balletto E, Varaldo R, et al
    Pre-engraftment bloodstream infection after allogeneic haematopoietic cell transplant: 18-year trends in aetiology, resistance and mortality.
    Bone Marrow Transplant. 2024 Dec 11. doi: 10.1038/s41409-024-02494.
    >> Share

  52. ESCAMILLA-GOMEZ V, Garcia Gutierrez V, Alcalde-Mellado P, Astibia-Mahillo B, et al
    Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
    Bone Marrow Transplant. 2024 Dec 11. doi: 10.1038/s41409-024-02483.
    >> Share

  53. MURATORE E, Gambuti G, Leardini D, Baccelli F, et al
    The EASIX score as a predictor of sinusoidal obstruction syndrome and nonrelapse mortality in paediatric patients receiving allogeneic haematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Dec 10. doi: 10.1038/s41409-024-02489.
    >> Share

  54. GRIEB N, Oeser A, Ferle M, Hanke F, et al
    Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Bone Marrow Transplant. 2024 Dec 5. doi: 10.1038/s41409-024-02490.
    >> Share

  55. SUN J, Zhang YC, Wei J, Xu YJ, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study.
    Bone Marrow Transplant. 2024 Dec 2. doi: 10.1038/s41409-024-02485.
    >> Share

    November 2024
  56. GIAMMARCO S, Maggi R, Di Marino L, Chiusolo P, et al
    The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience.
    Bone Marrow Transplant. 2024 Nov 21. doi: 10.1038/s41409-024-02475.
    >> Share

  57. GIAMMARCO S, Limongiello MA, Di Marino L, Metafuni E, et al
    The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA.
    Bone Marrow Transplant. 2024 Nov 20. doi: 10.1038/s41409-024-02479.
    >> Share

  58. MAINGUY A, Soussain C, Touitou V, Bennedjai A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.
    Bone Marrow Transplant. 2024 Nov 19. doi: 10.1038/s41409-024-02477.
    >> Share

  59. CHIN MM, Tamaresis JS, Johnston LJ, Lowsky R, et al
    Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.
    Bone Marrow Transplant. 2024 Nov 18. doi: 10.1038/s41409-024-02476.
    >> Share

  60. MOLINOS-QUINTANA A, Martinez-Cibrian N, Alonso-Saladrigues A, Galan-Gomez V, et al
    Successful allogeneic CD34(+) hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
    Bone Marrow Transplant. 2024 Nov 17. doi: 10.1038/s41409-024-02473.
    >> Share

  61. LI SQ, Yu CZ, Xu LP, Wang Y, et al
    Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.
    Bone Marrow Transplant. 2024 Nov 16. doi: 10.1038/s41409-024-02466.
    >> Share

  62. XU LP, Lu PH, Wu DP, Huang H, et al
    Correction: Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02438.
    >> Share

  63. MAMEZ AC, Pradier A, Morin S, Giannotti F, et al
    Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02458.
    >> Share

  64. JEKER B, Thalmann L, Bacher U, Nilius H, et al
    Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02468.
    >> Share

  65. SEVER M, Drozd-Sokolowska J, Gras L, Koster L, et al
    Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Nov 12. doi: 10.1038/s41409-024-02460.
    >> Share

  66. LI L, Chen Y, Chen T, Xu Y, et al
    Mismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China.
    Bone Marrow Transplant. 2024 Nov 8. doi: 10.1038/s41409-024-02454.
    >> Share

  67. ALEXANDER T, Badoglio M, Labopin M, Daikeler T, et al
    Monitoring and management of CMV and EBV after autologous haematopoietic stem cell transplantation for autoimmune diseases: a survey of the EBMT Autoimmune Diseases Working party (ADWP).
    Bone Marrow Transplant. 2024 Nov 7. doi: 10.1038/s41409-024-02461.
    >> Share

  68. MAHMOUDJAFARI Z, Bhatt V, Galvin J, Xue Z, et al
    Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.
    Bone Marrow Transplant. 2024 Nov 6. doi: 10.1038/s41409-024-02445.
    >> Share

    October 2024
  69. ZHANG ZL, Tong J, Lu RN, Scutt AM, et al
    Retraction Note: Therapeutic potential of non-adherent BM-derived mesenchymal stem cells in tissue regeneration.
    Bone Marrow Transplant. 2024 Oct 24. doi: 10.1038/s41409-024-02441.
    >> Share

  70. JUNEJA M, Prabahran A, Rawicki M, Chee LCY, et al
    The economic cost of care in poor graft function following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2024 Oct 24. doi: 10.1038/s41409-024-02452.
    >> Share

  71. WANG Y, Gao WH, Wang LN, Wang L, et al
    Post-transplant cyclophosphamide with post-engraftment anti-thymocyte globulin reduce moderate to severe chronic graft-versus-host disease in peripheral stem cell transplantation from HLA-matched unrelated and haploidentical donors.
    Bone Marrow Transplant. 2024 Oct 22. doi: 10.1038/s41409-024-02436.
    >> Share

  72. AVIGAN ZM, Arinsburg S, Pan D, Mark T, et al
    Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
    Bone Marrow Transplant. 2024 Oct 18. doi: 10.1038/s41409-024-02442.
    >> Share

  73. ALSULIMAN T, Psimaras D, Stocker N, Sestili S, et al
    Autologous hematopoietic stem cell transplantation in a patient with multi-refractory stiff person syndrome.
    Bone Marrow Transplant. 2024 Oct 17. doi: 10.1038/s41409-024-02440.
    >> Share

  74. HUANG XB, Yang X, Li CL, Zhang R, et al
    Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.
    Bone Marrow Transplant. 2024 Oct 14. doi: 10.1038/s41409-024-02433.
    >> Share

  75. YALCIN K, Uygun V, Ozturk Hismi B, Celen S, et al
    Hematopoietic stem cell transplantation in children with mucopolysaccharidosis IVA: single center experience.
    Bone Marrow Transplant. 2024 Oct 14. doi: 10.1038/s41409-024-02439.
    >> Share

  76. BEKADJA MA, Niederwiser D, Kharfan-Dabaja MA, El Fakih R, et al
    Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2024 Oct 7. doi: 10.1038/s41409-024-02431.
    >> Share

  77. SCHNEIDEWIND L, Neumann T, Peters N, Kranz J, et al
    Correction: Significance of men's health in long-term survivors of allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2024 Oct 4. doi: 10.1038/s41409-024-02415.
    >> Share

  78. BERTUGLIA G, Garibaldi B, Casson A, Sarina B, et al
    Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor.
    Bone Marrow Transplant. 2024 Oct 4. doi: 10.1038/s41409-024-02432.
    >> Share

    September 2024
  79. SHIMOMURA Y, Kitamura T, Sugita J, Terao T, et al
    Impact of donor type on the outcomes of acute graft versus host disease to systemic corticosteroid therapy.
    Bone Marrow Transplant. 2024 Sep 30. doi: 10.1038/s41409-024-02424.
    >> Share

  80. BAYOUMY M, Almasari A, Orabe A, Shihata N, et al
    Impact of JACIE accreditation on safety of patient care: healthcare providers perspective from a tertiary care stem cell transplant center in Saudi Arabia.
    Bone Marrow Transplant. 2024 Sep 28. doi: 10.1038/s41409-024-02387.
    >> Share

  81. XU LP, Lu PH, Wu DP, Huang H, et al
    Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.
    Bone Marrow Transplant. 2024 Sep 25. doi: 10.1038/s41409-024-02419.
    >> Share

  82. PEDERSEN LL, Gerbek T, Sorum ME, Muhic E, et al
    Dietary intake and risk of metabolic syndrome in long-term survivors of pediatric allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Sep 18. doi: 10.1038/s41409-024-02412.
    >> Share

  83. ALDEBERT C, Fahd M, Galimard JE, Ghemlas IA, et al
    Outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT.
    Bone Marrow Transplant. 2024 Sep 18. doi: 10.1038/s41409-024-02416.
    >> Share

  84. DUARTE GC, Ladvanszky L, Atkinson G, Burns M, et al
    Post-thaw CD34+ cell recovery likely degraded under extreme graft platelet concentrations.
    Bone Marrow Transplant. 2024 Sep 16. doi: 10.1038/s41409-024-02409.
    >> Share

  85. URIA-OFICIALDEGUI ML, Quintero V, Benitez-Carabante MI, Bueno D, et al
    Accurate donor and recipient selection and a short time to transplant offer excellent outcomes in upfront hematopoietic stem cell transplantation from matched unrelated donors for pediatric severe aplastic anemia and refractory cytopenia of childhood.
    Bone Marrow Transplant. 2024 Sep 3. doi: 10.1038/s41409-024-02406.
    >> Share

    August 2024
  86. ZHANG H, Guo W, Wang J, Lu N, et al
    Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Aug 27. doi: 10.1038/s41409-024-02402.
    >> Share

  87. SILFVERBERG T, Zjukovskaja C, Noui Y, Carlson K, et al
    BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis.
    Bone Marrow Transplant. 2024 Aug 26. doi: 10.1038/s41409-024-02397.
    >> Share

  88. XIE Y, Kazakova V, Weeks LD, Gerber JM, et al
    Effects of donor-engrafted clonal hematopoiesis in allogeneic and autologous stem cell transplantation: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Aug 25. doi: 10.1038/s41409-024-02403.
    >> Share

  89. ASENSI CANTO P, Gomez-Segui I, Montoro J, Villalba Montaner M, et al
    Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
    Bone Marrow Transplant. 2024 Aug 24. doi: 10.1038/s41409-024-02391.
    >> Share

  90. STEWART C, Owen C, Shafey M, Perry S, et al
    Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era.
    Bone Marrow Transplant. 2024 Aug 20. doi: 10.1038/s41409-024-02399.
    >> Share

  91. NAGLER A, Labopin M, Swoboda R, Blaise D, et al
    Young (<35 years) haploidentical versus old (>/=35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on
    Bone Marrow Transplant. 2024 Aug 18. doi: 10.1038/s41409-024-02400.
    >> Share

  92. JANSCAK M, Stelmes A, van den Berg J, Heim D, et al
    Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Aug 13. doi: 10.1038/s41409-024-02395.
    >> Share

  93. BEER SA, Mohle R, Tabatabai G, Merle DA, et al
    Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation.
    Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02382.
    >> Share

  94. DEN HARTOG E, Lindemans CA, Fiocco M, Tissing WJE, et al
    Physical performance before and after hematopoietic stem cell transplantation in pediatric patients: a potential role for prehabilitation.
    Bone Marrow Transplant. 2024 Aug 8. doi: 10.1038/s41409-024-02390.
    >> Share

  95. AL HAMED R, Labopin M, Wu D, Gedde-Dahl T, et al
    Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.
    Bone Marrow Transplant. 2024 Aug 2. doi: 10.1038/s41409-024-02373.
    >> Share

  96. LIU L, Han B, Zhang Y, Lei M, et al
    First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.
    Bone Marrow Transplant. 2024 Aug 1. doi: 10.1038/s41409-024-02377.
    >> Share

    July 2024
  97. AVIGAN ZM, Arinsburg S, Pan D, Mark T, et al
    Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
    Bone Marrow Transplant. 2024 Jul 31. doi: 10.1038/s41409-024-02385.
    >> Share

  98. VADAKKEL G, Eng S, Proli A, Ponce DM, et al
    Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era.
    Bone Marrow Transplant. 2024 Jul 31. doi: 10.1038/s41409-024-02370.
    >> Share

  99. HUSSEIN-AGHA R, Kannengiesser C, Lainey E, Marcais A, et al
    Alemtuzumab-based conditioning regimen before hematopoietic stem cell transplantation in patients with short telomere syndromes: a retrospective study of the SFGM-TC.
    Bone Marrow Transplant. 2024 Jul 30. doi: 10.1038/s41409-024-02381.
    >> Share

  100. WANG L, Gao W, Wang L, Jiang J, et al
    Impact of graft CD34+ cell counts on hematological recovery in patients receiving post-transplant cyclophosphamide prophylaxis.
    Bone Marrow Transplant. 2024 Jul 27. doi: 10.1038/s41409-024-02371.
    >> Share

  101. WANG J, Luo Y, Jia C, Yang J, et al
    Successful use of defibrotide to treat allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy in pediatric patients: report from Chinese single center.
    Bone Marrow Transplant. 2024 Jul 23. doi: 10.1038/s41409-024-02368.
    >> Share

  102. ESTEVE M, Albert E, Gimenez E, Colomer E, et al
    Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis.
    Bone Marrow Transplant. 2024 Jul 20. doi: 10.1038/s41409-024-02376.
    >> Share

  103. TSAKIRIS DA, Gavriilaki E, Chanou I, Meyer SC, et al
    Hemostasis and complement in allogeneic hematopoietic stem cell transplantation: clinical significance of two interactive systems.
    Bone Marrow Transplant. 2024 Jul 14. doi: 10.1038/s41409-024-02362.
    >> Share

  104. CHOI EJ, Han JH, Park H, Park HS, et al
    Lower incidence of acute graft-versus-host disease with post-transplantation cyclophosphamide compared to anti-thymocyte globulin in higher-risk myelodysplastic syndrome.
    Bone Marrow Transplant. 2024 Jul 8. doi: 10.1038/s41409-024-02364.
    >> Share

    June 2024
  105. YU Y, Chen W, Fu H, Shi J, et al
    Risk factors and long-term outcomes for human herpesvirus 6 encephalitis in the early period after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jun 27. doi: 10.1038/s41409-024-02332.
    >> Share

  106. SANZ MA, Montoro J, Balaguer-Rosello A, Chorao P, et al
    Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
    Bone Marrow Transplant. 2024 Jun 25. doi: 10.1038/s41409-024-02319.
    >> Share

  107. MARRERO-CEPEDA C, Caballero-Velazquez T, Garcia-Canale S, Martin-Dominguez F, et al
    Monocytosis as prognostic factor for chronic graft versus host disease.
    Bone Marrow Transplant. 2024 Jun 22. doi: 10.1038/s41409-024-02333.
    >> Share

  108. KELKAR AH, Kerssens C, Groblewski N, Clancy D, et al
    Human-in-the-loop avatar chatbot shows promise in supporting hematopoietic stem cell transplantation patients.
    Bone Marrow Transplant. 2024 Jun 20. doi: 10.1038/s41409-024-02334.
    >> Share

  109. ZHU J, Xu M, Ye Y, Ru Y, et al
    Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study.
    Bone Marrow Transplant. 2024 Jun 19. doi: 10.1038/s41409-024-02335.
    >> Share

  110. SCHOEMANS H, Burns LJ, Liptrott SJ, Murray J, et al
    Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working party.
    Bone Marrow Transplant. 2024 Jun 18. doi: 10.1038/s41409-024-02290.
    >> Share

  111. BOULKROUN H, Lacotte E, Angoso M, Dalle JH, et al
    Late stenosis of the small intestine and colon, an atypical feature of chronic graft-versus-host disease. National retrospective study in French pediatric allograft centers.
    Bone Marrow Transplant. 2024 Jun 17. doi: 10.1038/s41409-024-02330.
    >> Share

  112. STEINER N, Massoud R, Klyuchnikov E, Gagelmann N, et al
    Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jun 14. doi: 10.1038/s41409-024-02328.
    >> Share

  113. AVENOSO D, Lionel S, Maraj A
    Second allogeneic haematopoietic stem cell transplant conditioned with treosulfan and fludarabine is associated with encouraging overall survival and transplant related mortality in late relapse of myeloid malignancies.
    Bone Marrow Transplant. 2024 Jun 13. doi: 10.1038/s41409-024-02329.
    >> Share

  114. ORCHARD K, Langford J, Guy M, Lewis G, et al
    Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jun 12. doi: 10.1038/s41409-024-02317.
    >> Share

  115. MARTINEZ-MUNOZ ME, Payares-Herrera C, Lipperheide I, Malo de Molina R, et al
    Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
    Bone Marrow Transplant. 2024;59:777-784.
    >> Share

    May 2024
  116. SINGH RB, Cho W, Liu C, Naderi A, et al
    Immunopathological mechanisms and clinical manifestations of ocular graft-versus-host disease following hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 May 31. doi: 10.1038/s41409-024-02321.
    >> Share

  117. FERNANDEZ-SOJO J, Azqueta C, Valdivia E, Martorell L, et al
    Correction: Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?
    Bone Marrow Transplant. 2024 May 28. doi: 10.1038/s41409-024-02318.
    >> Share

  118. TERAO T, Matsuoka KI, Fuji S, Kawamura S, et al
    Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era.
    Bone Marrow Transplant. 2024 May 25. doi: 10.1038/s41409-024-02313.
    >> Share

  119. XHAARD A, Floch A, Ruggiu M, Robin M, et al
    Donor/recipient Rh-mismatched allogeneic hematopoietic stem cell transplantation: transfusion strategy and allo-immunization to red blood cell antigens.
    Bone Marrow Transplant. 2024 May 25. doi: 10.1038/s41409-024-02316.
    >> Share

  120. ROBIN M, Nibourel O, Tournaire M, Michonneau D, et al
    Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen.
    Bone Marrow Transplant. 2024 May 23. doi: 10.1038/s41409-024-02314.
    >> Share

  121. HU X, Wang Z, Qin Y, Xu J, et al
    Allogeneic haematopoietic stem cell transplantation might overcome the poor prognosis of adolescents and adult patients with T-lineage acute lymphoblastic leukaemia and CDKN2 deletion.
    Bone Marrow Transplant. 2024 May 20. doi: 10.1038/s41409-024-02306.
    >> Share

  122. PARK B, Pires K, Jian CY, Sano L, et al
    A library of TikToks to engage diverse populations to hematopoietic stem cell donation.
    Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02294.
    >> Share

  123. MORA E, Montoro J, Balaguer A, Rovira M, et al
    Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02298.
    >> Share

  124. ROBIN M, Iacobelli S, Koster L, Passweg J, et al
    Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 May 13. doi: 10.1038/s41409-024-02293.
    >> Share

  125. PEREZ A, Gomez D, Montoro J, Chorao P, et al
    Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease.
    Bone Marrow Transplant. 2024 May 10. doi: 10.1038/s41409-024-02304.
    >> Share

  126. SINANIDIS I, Hochman MJ, Tsai HL, Randall MP, et al
    Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.
    Bone Marrow Transplant. 2024 May 7. doi: 10.1038/s41409-024-02299.
    >> Share

  127. BERNING P, Kolloch L, Reicherts C, Call S, et al
    Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.
    Bone Marrow Transplant. 2024 May 3. doi: 10.1038/s41409-024-02295.
    >> Share

  128. AYUK F, Wagner-Drouet EM, Wolff D, von Huenerbein N, et al
    Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study.
    Bone Marrow Transplant. 2024 May 2. doi: 10.1038/s41409-024-02289.
    >> Share

    April 2024
  129. DAVIDOV Y, Shem-Tov N, Yerushalmi R, Hod T, et al
    Liver stiffness measurements predict Sinusoidal Obstructive Syndrome after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Apr 24. doi: 10.1038/s41409-024-02288.
    >> Share

  130. XU W, Chen W, Guo J, Zhao L, et al
    Acute kidney injury during autologous stem cell transplantation in light chain amyloidosis with kidney involvement and their impact on prognosis.
    Bone Marrow Transplant. 2024 Apr 24. doi: 10.1038/s41409-024-02292.
    >> Share

  131. ALSUHEBANY N, Alshehri B, Aldairem A, Aleissa MM, et al
    Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage.
    Bone Marrow Transplant. 2024 Apr 16. doi: 10.1038/s41409-024-02273.
    >> Share

  132. NAGLER A, Labopin M, Swoboda R, Schroeder T, et al
    Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplanta
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284.
    >> Share

  133. SHEN Y, Liu M, Shen D, Chu M, et al
    Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02280.
    >> Share

  134. TAHMAZ V, Menghesha L, Stern ME, Holtick U, et al
    Insulin eye drops for severe refractory chronic ocular graft-versus-host disease.
    Bone Marrow Transplant. 2024 Apr 10. doi: 10.1038/s41409-024-02272.
    >> Share

  135. WANG L, Xu G, Wang L, Jiang J, et al
    Post-transplant cyclophosphamide at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning.
    Bone Marrow Transplant. 2024 Apr 10. doi: 10.1038/s41409-024-02277.
    >> Share

  136. FILIOGLOU D, Truscott L, Reddivalla N, Katsanis E, et al
    Outcomes of haploidentical bone marrow transplantation in infant acute leukemia: a single center experience.
    Bone Marrow Transplant. 2024 Apr 9. doi: 10.1038/s41409-024-02281.
    >> Share

  137. ZHANG X, Zhao X, Chen S, Hao M, et al
    Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.
    Bone Marrow Transplant. 2024 Apr 5. doi: 10.1038/s41409-024-02266.
    >> Share

  138. MA R, Zhu DP, Zhang XH, Xu LP, et al
    Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience.
    Bone Marrow Transplant. 2024 Apr 2. doi: 10.1038/s41409-024-02276.
    >> Share

    March 2024
  139. KOO RM, Wong E, Davis JE, Perera T, et al
    A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome.
    Bone Marrow Transplant. 2024 Mar 27. doi: 10.1038/s41409-023-02195.
    >> Share

  140. ESTRAN S, Loschi M, Benachour S, Soldati A, et al
    Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial.
    Bone Marrow Transplant. 2024 Mar 20. doi: 10.1038/s41409-024-02271.
    >> Share

  141. GUIEZE R, Eikema DJ, Koster L, Schetelig J, et al
    Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Mar 19. doi: 10.1038/s41409-024-02256.
    >> Share

  142. YADAV H, Herasevich S, Zhang Z, White BA, et al
    Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study.
    Bone Marrow Transplant. 2024 Mar 16. doi: 10.1038/s41409-024-02265.
    >> Share

  143. ROBIN M, Iacobelli S, Koster L, Passweg J, et al
    Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Mar 15. doi: 10.1038/s41409-024-02269.
    >> Share

  144. FURST S, Bernit E, Legrand F, Granata A, et al
    Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease.
    Bone Marrow Transplant. 2024 Mar 14. doi: 10.1038/s41409-024-02257.
    >> Share

  145. SAUER S, Engelhardt M, Trautmann-Grill K, Kimmich C, et al
    Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany.
    Bone Marrow Transplant. 2024 Mar 14. doi: 10.1038/s41409-024-02208.
    >> Share

  146. MORRIS SL, Thomas BR, Palanicawandar R, Whittaker S, et al
    Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Bone Marrow Transplant. 2024 Mar 12. doi: 10.1038/s41409-024-02236.
    >> Share

  147. FRAEBEL J, Park S, Shah R, Prieto-Granada C, et al
    GVHD like skin eruption post-autologous stem cell transplantation.
    Bone Marrow Transplant. 2024 Mar 11. doi: 10.1038/s41409-024-02259.
    >> Share

  148. FAZIO F, Passucci M, Micozzi J, Di Landro F, et al
    Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.
    Bone Marrow Transplant. 2024 Mar 9. doi: 10.1038/s41409-024-02260.
    >> Share

  149. DACHY G, Vankeerbergen M, Vanlangendonck N, Straetmans N, et al
    Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Mar 8. doi: 10.1038/s41409-024-02242.
    >> Share

  150. CHU SC, Hsieh CJ, Li CC, Yang SH, et al
    Long-term follow-up of cancer and catastrophic diseases in hematopoietic stem cell donors: a comprehensive matched cohort study.
    Bone Marrow Transplant. 2024 Mar 7. doi: 10.1038/s41409-024-02204.
    >> Share

  151. SHANG Q, Bai L, Cheng Y, Suo P, et al
    Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia.
    Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02214.
    >> Share

  152. PARK S, Bang SY, Kwag D, Lee JH, et al
    Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
    Bone Marrow Transplant. 2024 Mar 4. doi: 10.1038/s41409-024-02255.
    >> Share

    February 2024
  153. YANG YM, Guo SJ, Xiao R, Yu XJ, et al
    Prevalence of osteoporosis among patients after stem cell transplantation: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Feb 29. doi: 10.1038/s41409-024-02243.
    >> Share

  154. BACCELLI F, Gottardi F, Muratore E, Leardini D, et al
    Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
    Bone Marrow Transplant. 2024 Feb 24. doi: 10.1038/s41409-024-02252.
    >> Share

  155. FINAZZI MC, Weber A, Pavoni C, Grassi A, et al
    Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Feb 24. doi: 10.1038/s41409-024-02247.
    >> Share

  156. MURRAY A, Linn SM, Yu B, Novitzky-Basso I, et al
    Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease.
    Bone Marrow Transplant. 2024 Feb 24. doi: 10.1038/s41409-024-02249.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016